Cargando…

The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1)

The 2021 VCP Scientific Conference took place virtually from September 9–10, 2021. This conference, planned and organized by the nonprofit patient advocacy group Cure VCP Disease, Inc. (https://www.curevcp.org), was the first VCP focused meeting since the 215th ENMC International Workshop VCP-relate...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Michelle A., Klickstein, Jacob A., Khanna, Richa, Gou, Yunzi, Raman, Malavika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169230/
https://www.ncbi.nlm.nih.gov/pubmed/35405261
http://dx.doi.org/10.1016/j.nbd.2022.105722
_version_ 1784721164375949312
author Johnson, Michelle A.
Klickstein, Jacob A.
Khanna, Richa
Gou, Yunzi
Raman, Malavika
author_facet Johnson, Michelle A.
Klickstein, Jacob A.
Khanna, Richa
Gou, Yunzi
Raman, Malavika
author_sort Johnson, Michelle A.
collection PubMed
description The 2021 VCP Scientific Conference took place virtually from September 9–10, 2021. This conference, planned and organized by the nonprofit patient advocacy group Cure VCP Disease, Inc. (https://www.curevcp.org), was the first VCP focused meeting since the 215th ENMC International Workshop VCP-related multi-system proteinopathy in 2016 (Evangelista et al., 2016). Mutations in VCP cause a complex and heterogenous disease termed inclusion body myopathy (IBM) with Paget’s disease of the bone (PDB) and frontotemporal dementia (FTD) (IBMPFD), or multisystem proteinopathy 1 (MSP-1) Kimonis (n.d.), Kovach et al. (2001), Kimonis et al. (2000). In addition, VCP mutations also cause other age-related neurodegenerative disorders including amyptrophic lateral sclerosis (ALS), Parkinsonism, Charcot-Marie type II-B, vacuolar tauopathy among others (Korb et al., 2022). The objectives of this conference were as follows: (1) to provide a forum that facilitates sharing of published and unpublished information on physiological roles of p97/VCP, and on how mutations of VCP lead to diseases; (2) to bolster understanding of mechanisms involved in p97/VCP-relevant diseases and to enable identification of therapeutics to treat these conditions; (3) to identify gaps and barriers of further discoveries and translational research in the p97/VCP field; (4) to set a concrete basic and translational research agenda for future studies including crucial discussions on biomarker discoveries and patient longitudinal studies to facilitate near-term clinical trials; (5) to accelerate cross-disciplinary research collaborations among p97/VCP researchers; (6) to enable attendees to learn about new tools and reagents with the potential to facilitate p97/VCP research; (7) to assist trainees in propelling their research and to foster mentorship from leaders in the field; and (8) to promote diversity and inclusion of under-represented minorities in p97/VCP research as diversity is critically important for strong scientific research. Given the range of topics, the VCP Scientific Conference brought together over one hundred and forty individuals representing a diverse group of research scientists, trainees, medical practitioners, industry representatives, and patient advocates. Twenty-five institutions with individuals from thirteen countries attended this virtual meeting. In this report, we summarize the major topics presented at this conference by a range of experts.
format Online
Article
Text
id pubmed-9169230
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-91692302022-07-01 The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1) Johnson, Michelle A. Klickstein, Jacob A. Khanna, Richa Gou, Yunzi Raman, Malavika Neurobiol Dis Article The 2021 VCP Scientific Conference took place virtually from September 9–10, 2021. This conference, planned and organized by the nonprofit patient advocacy group Cure VCP Disease, Inc. (https://www.curevcp.org), was the first VCP focused meeting since the 215th ENMC International Workshop VCP-related multi-system proteinopathy in 2016 (Evangelista et al., 2016). Mutations in VCP cause a complex and heterogenous disease termed inclusion body myopathy (IBM) with Paget’s disease of the bone (PDB) and frontotemporal dementia (FTD) (IBMPFD), or multisystem proteinopathy 1 (MSP-1) Kimonis (n.d.), Kovach et al. (2001), Kimonis et al. (2000). In addition, VCP mutations also cause other age-related neurodegenerative disorders including amyptrophic lateral sclerosis (ALS), Parkinsonism, Charcot-Marie type II-B, vacuolar tauopathy among others (Korb et al., 2022). The objectives of this conference were as follows: (1) to provide a forum that facilitates sharing of published and unpublished information on physiological roles of p97/VCP, and on how mutations of VCP lead to diseases; (2) to bolster understanding of mechanisms involved in p97/VCP-relevant diseases and to enable identification of therapeutics to treat these conditions; (3) to identify gaps and barriers of further discoveries and translational research in the p97/VCP field; (4) to set a concrete basic and translational research agenda for future studies including crucial discussions on biomarker discoveries and patient longitudinal studies to facilitate near-term clinical trials; (5) to accelerate cross-disciplinary research collaborations among p97/VCP researchers; (6) to enable attendees to learn about new tools and reagents with the potential to facilitate p97/VCP research; (7) to assist trainees in propelling their research and to foster mentorship from leaders in the field; and (8) to promote diversity and inclusion of under-represented minorities in p97/VCP research as diversity is critically important for strong scientific research. Given the range of topics, the VCP Scientific Conference brought together over one hundred and forty individuals representing a diverse group of research scientists, trainees, medical practitioners, industry representatives, and patient advocates. Twenty-five institutions with individuals from thirteen countries attended this virtual meeting. In this report, we summarize the major topics presented at this conference by a range of experts. 2022-07 2022-04-08 /pmc/articles/PMC9169230/ /pubmed/35405261 http://dx.doi.org/10.1016/j.nbd.2022.105722 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Article
Johnson, Michelle A.
Klickstein, Jacob A.
Khanna, Richa
Gou, Yunzi
Raman, Malavika
The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1)
title The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1)
title_full The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1)
title_fullStr The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1)
title_full_unstemmed The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1)
title_short The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1)
title_sort cure vcp scientific conference 2021: molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (msp-1)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169230/
https://www.ncbi.nlm.nih.gov/pubmed/35405261
http://dx.doi.org/10.1016/j.nbd.2022.105722
work_keys_str_mv AT johnsonmichellea thecurevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1
AT klicksteinjacoba thecurevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1
AT khannaricha thecurevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1
AT gouyunzi thecurevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1
AT thecurevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1
AT ramanmalavika thecurevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1
AT johnsonmichellea curevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1
AT klicksteinjacoba curevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1
AT khannaricha curevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1
AT gouyunzi curevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1
AT curevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1
AT ramanmalavika curevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1